Q32 Bio Inc 2026年季度报告

(Mark One)☒QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF1934 For the quarterly period ended March 31, 2026OR ☐TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF1934 For the transition period from ___________________ to ___________________Commission File Number: 001-38433 Q32 Bio Inc. (Exact name of Registrant as specified in its Charter) Registrant’s telephone number, including area code: (781) 999-0232N/A(Former name, former address and former fiscal year, if changed since last report) Securities registered pursuant to Section 12(b) of the Act: Indicate by check mark whether the Registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Actof 1934 during the preceding 12 months (or for such shorter period that the Registrant was required to file such reports), and (2) has been subjectto such filing requirements for the past 90 days.Yes☒No☐ Indicate by check mark whether the Registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule405 of Regulation S-T (§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the Registrant was required tosubmit such files).Yes☒No☐ Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company,or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company,” and “emerginggrowth company” in Rule 12b-2 of the Exchange Act. Accelerated filer☐Smaller reporting company☒Emerging growth company☐ Large accelerated filer☐Non-accelerated filer☒ If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying withany new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.☐ Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act).Yes☐No☒As of May 1, 2026, the registrant had 16,956,415 shares of common stock, $0.0001 par value per share, outstanding. Our ability to implement our business strategy is subject to numerous risks that you should be aware of before making aninvestment decision. These risks include the following, among others: •We have incurred significant operating losses since inception, expect to incur significant losses for the foreseeablefuture and may not be able to achieve or sustain profitability in the future. We have no products for sale, have notgenerated any product revenue and may never generate product revenue or become profitable.•We will require substantial additional capital to finance our operations in the future. If we are unable to raise suchcapital when needed, or on acceptable terms, we may be forced to delay, reduce or eliminate clinical trials, productdevelopment programs or future commercialization efforts.•We have a limited operating history and have no products approved for commercial sale, which may make it difficultfor you to evaluate our current business and likelihood of success and viability.•We face competition from entities that have developed or may develop programs for the diseases we plan to addresswith bempikibart or other product candidates.•Bempikibart and the rest of our pipeline are in early stages of development and may fail in development or suffer delaysthat materially and adversely affect their commercial viability. If we or our current or future collaborators are unable tocomplete development of, or commercialize, our product candidates, or experience significant delays in doing so, ourbusiness will be materially harmed.•We are substantially dependent on the success of our most advanced product candidate, bempikibart, and our clinicaltrials of our lead candidate may not be successful.•Our rights to develop and commercialize our product candidates are, and in the future may be, subject to the terms andconditions of licenses granted to us by others. If we fail to comply with our obligations in the agreements under whichwe license intellectual property rights from third parties, or these agreements are terminated, or we otherwiseexperience disruption to our business relationships with our licensors, we could lose license rights that are important toour business.•Our ability to protect our patents and other proprietary rights is uncertain, exposing us to the possible loss ofcompetitive advantage.•Our business could be adversely affected by economic downturns, inflation, changes in interest rates, natural disasters,public health crises, political crises, government shutdowns, geopolitical events or other macroeconomic conditions,which could have a material and adverse effect on our results of operations and financial condition.•We rely on third parties in the supply and manufacture of our product